NCT05705089 (REWARF-STEMI) is a Phase 3 clinical trial of Rivaroxaban 15 MG in Left Ventricular Thrombus, sponsored by Rajaie Cardiovascular Medical and Research Center.

Who is sponsoring NCT05705089?

NCT05705089 is sponsored by Rajaie Cardiovascular Medical and Research Center.

What drugs are being tested in NCT05705089?

Interventions in NCT05705089: Rivaroxaban 15 MG, Warfarin.

What condition does NCT05705089 study?

NCT05705089 studies Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction.

Is NCT05705089 still recruiting?

NCT05705089 is currently completed. Last updated 7 April 2023.

Last reviewed 2023-04-07 · How we verify

NCT05705089: REWARF-STEMI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI

Completed Phase 3 Last updated 7 April 2023

What this trial tests

Phase 3 trial testing Rivaroxaban 15 MG in Left Ventricular Thrombus in 50 participants. Completed in 1 April 2023.

Timeline

30 July 2020

Primary endpoint
1 February 2023

1 April 2023

Quick facts

Lead sponsor	Rajaie Cardiovascular Medical and Research Center
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	50
Start date	30 July 2020
Primary completion	1 February 2023
Estimated completion	1 April 2023
Sites	2 locations across Iran

Drugs / interventions tested

Rivaroxaban 15 MG
Warfarin (warfarin) — full drug profile →

Conditions studied

Left Ventricular Thrombus — all drugs for Left Ventricular Thrombus →
ST Segment Elevation Myocardial Infarction — all drugs for ST Segment Elevation Myocardial Infarction →

Sponsor

Rajaie Cardiovascular Medical and Research Center — full company profile →

Who can join

Adults 18 to 80, any sex, with Left Ventricular Thrombus or ST Segment Elevation Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to assess the safety and efficacy of rivaroxaban-based versus warfarin-based antithrombotic regimens on outcomes of patients with left ventricle thrombosis following acute ST elevation myocardial infarction at 3 months from enrollment in an open-label parallel groups pilot randomized clinical trial

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials.
Jenab Y, Sadeghipour P, Mohseni-Badalabadi R, Kaviani R, et al · · 2025 · cited 18× · PMID 39773831 · DOI 10.4244/eij-d-24-00527
Trial sequential analysis of efficacy and safety of direct oral anticoagulants and vitamin K antagonists against left ventricular thrombus.
Kitano T, Nabeshima Y, Kataoka M, Takeuchi M. · · 2023 · cited 6× · PMID 37580355 · DOI 10.1038/s41598-023-40389-x
Decoding vascular calcification: mechanistic insights and translational strategies.
Adelnia H, Ray S, Ta HT. · · 2026 · PMID 41665680 · DOI 10.1007/s00018-026-06086-4
Efficacy and safety of direct oral anticoagulants versus warfarin in patients with a left ventricular thrombus: an updated systematic review and meta-analysis of randomised controlled trials.
Costa TA, Chagas GCL, Tavares de Sousa LM, Lins de Souza B, et al · · 2025 · PMID 41265923 · DOI 10.1136/openhrt-2025-003542

Verify or expand the search:

Other trials of Rivaroxaban 15 MG

Trials testing the same drug.

NCT06187311 — Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrill · Phase 4 · recruiting
NCT05669313 — The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM · completed
NCT05233124 — Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia · Phase 2 · unknown

Other recruiting trials for Left Ventricular Thrombus

Currently open trials in the same condition.

NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
NCT06742567 — Apixaban Prophylaxis for Prevention of Left Ventricular Thrombus Following Anterior Myocardial Infarction · Phase 3 · recruiting

Other Rajaie Cardiovascular Medical and Research Center trials

Trials by the same sponsor.

NCT06541691 — Coated or Chewable Aspirin and a Hybrid Strategy to Mitigate Adverse Effects of Air Pollution in Stable Atherosclerotic · NA · recruiting
NCT06124937 — Empagliflozin to Prevent Post-Operative Atrial Fibrillation · Phase 3 · unknown
NCT04486508 — Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19 · Phase 3 · completed
NCT04304118 — Rajaie Cardiomyopathy and Myocarditis Registry · unknown
NCT03926156 — RIvoraxaban in Mitral Stenosis · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05705089 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rajaie Cardiovascular Medical and Research Center
Last refreshed: 7 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05705089.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing